Vir Biotechnology, Inc. (VIR): M&A transaction — Vir closes $100M Sanofi license deal for three T-cell engagers; appoints new CFO

Vir Biotechnology, Inc.

Closed exclusive worldwide license with Sanofi for 3 clinical-stage masked TCEs (SAR446309, SAR446329, SAR446368) and PRO-XTEN platform for oncology/infectious disease.
Upfront payment $100M plus $75M escrowed milestone; up to $323M dev/reg milestones, $1.488B sales milestones, and low single to low double-digit tiered royalties.
Jason O'Byrne appointed EVP and CFO effective Oct 2, 2024; base salary $530K, target bonus 45%, sign-on $450K, equity awards of 150K options and 75K RSUs.
Clinical assets: SAR446309 (HER2) in Phase 1, SAR446329 (PSMA) in Phase 1, SAR446368 (EGFR) IND active, Phase 1 start expected Q1 2025.

item 2.01 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jason O'Byrne

Executive Vice President and Chief Financial Officer

VIR · Vir Biotechnology, Inc.

Effective: 2024-10-02
Filed: September 10, 2024, 7:59 PM ET

the Company announced that Jason O’Byrne, MBA, has been appointed as Executive Vice President and Chief Financial Officer and “principal financial officer” of the Company, effective as of October 2, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jason O'Byrne was appointed as Executive Vice President and Chief Financial Officer at Vir Biotechnology, Inc..

Action: appointed
Role: Executive Vice President and Chief Financial Officer

Exact text from the filing

the Company announced that Jason O’Byrne, MBA, has been appointed as Executive Vice President and Chief Financial Officer and “principal financial officer” of the Company, effective as of October 2, 2024

View on SEC.gov

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Vir Biotechnology, Inc. completed an acquisition involving Sanofi for $100 million plus $75 million in an escrowed milestone payment (closed 2024-09-09).

Action: acquisition
Counterparty: Sanofi
Consideration: $100 million plus $75 million in an escrowed milestone payment
Closing: 2024-09-09

Exact text from the filing

masking platform for oncology and infectious disease, acquired by Sanofi from Amunix. At Closing, the Company made an upfront payment to Sanofi in the amount of $100 million plus $75 million in an escrowed milestone payment that is subject to SAR446368 (AMX-525) achieving “first in human dosing” by 2026. Sanofi will also be eligible to receive up to

View on SEC.gov

9 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Vir Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-039948

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.